By a News Reporter-Staff News Editor at VerticalNews Health A majority of patients in the United States visited a doctor who received payments from drug companies, but most have no clue about it, according to a new Drexel University study. About 65 percent of those surveyed as a part of the study by Genevieve Pham-Kanter, PhD, an assistant profes
European Society for Blood and Marrow Transplantation 2017- Marseille, FranceMarch 27, 2017, 9:00- 9:10am Oral Session 3: Novel drugs and immunotherapies Title: Drug Resistant Lymphocyte Immunotherapy: Dose and Schedule OptimizationPresenter: Lawrence Lamb. American Association for Cancer Research 2017- Washington DC, USAApril 3, 2017, 8:00- 12:00p
Attorney Advertising. On March 17, 2017, the nationally recognized class-action law firm of Keller Rohrback L.L.P. filed suit against the nation s three largest pharmacy benefit managers, Express Scripts, OptumRx, and CVS Caremark, and the three major insulin manufacturers, Sanofi-Aventis, Novo Nordisk, and Eli Lilly, who produce the well-known
-Neuren Pharmaceuticals has reported top-line results for its Phase 2 clinical trial in girls with Rett syndrome aged 5 to 15. Neuren now intends to discuss with the US Food and Drug Administration plans for a pivotal trial commencing in 2018 using the Rett Syndrome Behaviour Questionnaire as a primary efficacy measure, supported by the Clinical Gl
MILAN& MORRISTOWN, N.J. Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system and pain, today presented detailed results of a Phase IIa study with its unique sodium channel blocker, Evenamide, in patients with schizophrenia. The results w
-Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today opened its expanded office in King of Prussia, Pennsylvania. Our expanded home in King of Prussia provides our growing team with the physical space and resources to fuel our...
-Profound Medical Corp. an emerging medical device company focused on prostate care, today announced that Steven Plymale has resigned his position as the Companys President and Chief Operating Officer to pursue other opportunities. The Company is also sponsoring a multicenter, prospective FDA- registered clinical trial, TACT, which is designed to f
March 25 Here are reactions from members of the Rhode Island congressional delegation and Gov. Perhaps in the future, President Trump and the Republicans will listen to the American people who want us to focus on affordable health care for all Americans, lower prescription drug prices, and tax cuts for the middle-class, not the wealthiest. "
The old and the poor made out great when House Republicans failed Friday to dismantle Barack Obama's Affordable Care Act. The measure would have repealed major parts of Obama's health law, capping future funding for Medicaid and cutting tax increases for high-income families, health insurance companies and drugmakers. That's the tally according
By a News Reporter-Staff News Editor at Investment Weekly News Researchers detail new data in Finance. The news correspondents obtained a quote from the research from Bangor University, "Cases were defined as holders of orphan drug market authorisation in Europe or the USA between 2000-12. Control companies were selected based on their propensity
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Lee, Catherine; Wang, Chien-Chiao, filed on November 14, 2016, was made available online on March 9, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to TAHO Pharmaceuticals Ltd.
Media coverage has been huge in Britain and King's homeland, Australia, while U.S. attention has been scant. The years-long route from lab rats to FDA drug approval will be painstaking, exacting, and not necessarily successful. Larry Goldstein, professor and chairman of the Department of Neurology at the University of Kentucky and past chair of The
AARP, a nonprofit, nonpartisan, social welfare organization, released a scathing assessment of the Republican-proposed health care bill that's facing opposition from not only Democrats but a segment of the GOP in the U.S. House of Representatives. AARP is strongly against the age tax and other aspects of the bill that will give tax breaks to drug c
By a News Reporter-Staff News Editor at Drug Week Amring Pharmaceuticals Inc., a generic pharmaceutical company, announced that it acquired six ANDAs from Luitpold Pharmaceuticals, Inc. and AlphaForce, L.L.P., a joint venture between Luitpold Pharmaceuticals, Inc. and Alphagen Laboratories Inc. Acquired ANDAs include niche otic and ophthalmic...
Analyst Ratings For Ascendis Pharma A/S (NASDAQ:ASND) Today, Wedbush raised its price target on Ascendis Pharma A/S (NASDAQ:ASND) to per share. There are 1 hold rating, 2 buy ratings on the stock. The current consensus rating on Ascendis Pharma A/S (NASDAQ:ASND) is Buy (Score: 2.67) with a consensus target price of $30.67 per share, a [?]
Analyst Ratings For Ascendis Pharma A/S (NASDAQ:ASND) Today, Wedbush raised its price target on Ascendis Pharma A/S (NASDAQ:ASND) to $34.00 per share. There are 1 hold rating, 2 buy ratings on the stock. The current consensus rating on Ascendis Pharma A/S (NASDAQ:ASND) is Buy (Score: 2.67) with a consensus target price of $30.67 per share, [?]
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Arbutus Biopharma Corp. was posted on March 6, 2017. The SEC file number is 0001171843-17-001299.. A U.S. Securities and Exchange Commission filing is a formal
AveXis, a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, reported topline results from the Phase 1 trial of AVXS-101 in spinal muscular atrophy Type 1. The completion of our Phase 1 clinical study of AVXS-101, the first ever gene therapy studied for the.
VALENCIA, Calif.& PERTH, Australia& LONDON Avita Medical Limited, a regenerative medicine company focused on the treatment of wounds and skin defects, today announced that Adam Kelliher, Avita s Chief Executive Officer will present at the 16th Annual Needham Healthcare Conference on 4 April 2017. The presentation will take place at 9:20am ET
By a News Reporter-Staff News Editor at Drug Week- InvestorsObserver issues critical PriceWatch Alerts for C, EXEL, GILD, TSLA, and USO. Gilead Sciences Inc is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors. Tesla Inc, formerly Tesla Motors Inc designs, develops,.
"Global Transdermal Patch Market& Clinical Pipeline Outlook 2022" report discusses the ongoing clinical and non-clinical parameters with respect to development of global transdermal patch market. Report highlights the need for integration of transdermal patches in existing drug delivery methodology available to pharmaceutical companies.
The Chinese infectious disease drug market is big, fast-growing and dominated by brands from outside China. This market is very important for pharmaceutical companies in North America, Europe and other developed regions that look for strong growth and high profits in the following decade. The goal of this study is to help readers achieve a comprehe
According to new report by Grand View Research, The Global bioinformatics market size was valued at USD 3.51 billion in 2013. Growing clinical development of biopharmaceutical and increasing need for three dimensional drug designing technology are expected to drive the market. The global bioinformatics market is expected to reach USD 13.47 billion
By a News Reporter-Staff News Editor at Drug Week Treatment of Crohn's disease and ulcerative colitis has been greatly improved by the introduction of biologic therapies such as infliximab, but at considerable cost. CT-P13 has been recently approved in the United States, the European Union, Australia, Canada, Japan, and many other countries.
This Friday, Stock-Callers.com has initiated reports coverage on the following Biotechnology equities: BioDelivery Sciences International Inc., Sage Therapeutics Inc., Benitec Biopharma Ltd, and OncoGenex Pharmaceuticals Inc.. On Thursday, shares in Raleigh, North Carolina headquartered BioDelivery Sciences International Inc. ended the session...